Clinical Trial Update: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating secukinumab plus standard of care versus placebo in active lupus nephritis was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lupus Nephritis | Phase 3 | Status: TERMINATED | Results posted: 2024-10-10